Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: HSPA5

Gene summary for HSPA5

Gene summary.

Gene information	Species	Human
	Gene symbol	HSPA5
	Gene ID	3309
	Gene name	heat shock protein family A (Hsp70) member 5
	Gene Alias	BIP
	Cytomap	9q33.3
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	P11021

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
3309	HSPA5	GSM4909282	Human	Breast	IDC	1.49e-02	-3.95e-01	-0.0288
3309	HSPA5	GSM4909285	Human	Breast	IDC	1.29e-02	1.30e-01	0.21
3309	HSPA5	GSM4909286	Human	Breast	IDC	5.38e-21	-6.23e-01	0.1081
3309	HSPA5	GSM4909287	Human	Breast	IDC	3.36e-07	3.56e-01	0.2057
3309	HSPA5	GSM4909290	Human	Breast	IDC	8.51e-08	-4.22e-01	0.2096
3309	HSPA5	GSM4909293	Human	Breast	IDC	5.55e-03	-4.45e-02	0.1581
3309	HSPA5	GSM4909294	Human	Breast	IDC	1.49e-09	-4.84e-01	0.2022
3309	HSPA5	GSM4909296	Human	Breast	IDC	7.65e-10	-4.23e-01	0.1524
3309	HSPA5	GSM4909297	Human	Breast	IDC	1.26e-09	-3.70e-01	0.1517
3309	HSPA5	GSM4909298	Human	Breast	IDC	3.65e-11	-4.26e-01	0.1551
3309	HSPA5	GSM4909302	Human	Breast	IDC	3.52e-14	-5.10e-01	0.1545
3309	HSPA5	GSM4909304	Human	Breast	IDC	1.89e-03	-3.23e-01	0.1636
3309	HSPA5	GSM4909305	Human	Breast	IDC	3.39e-04	-3.44e-01	0.0436
3309	HSPA5	GSM4909306	Human	Breast	IDC	2.41e-09	-5.12e-01	0.1564
3309	HSPA5	GSM4909307	Human	Breast	IDC	4.78e-16	-6.13e-01	0.1569
3309	HSPA5	GSM4909308	Human	Breast	IDC	4.57e-12	-4.90e-01	0.158
3309	HSPA5	GSM4909309	Human	Breast	IDC	2.73e-18	-5.98e-01	0.0483
3309	HSPA5	GSM4909311	Human	Breast	IDC	1.51e-23	-5.13e-01	0.1534
3309	HSPA5	GSM4909312	Human	Breast	IDC	2.80e-09	-3.82e-01	0.1552
3309	HSPA5	GSM4909313	Human	Breast	IDC	1.01e-10	-4.32e-01	0.0391

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0010975110	Thyroid	PTC	regulation of neuron projection development	194/5968	445/18723	1.05e-07	2.08e-06	194
GO:0042594111	Thyroid	PTC	response to starvation	98/5968	197/18723	1.24e-07	2.41e-06	98
GO:0021762112	Thyroid	PTC	substantia nigra development	31/5968	44/18723	1.70e-07	3.19e-06	31
GO:0006984110	Thyroid	PTC	ER-nucleus signaling pathway	32/5968	46/18723	1.72e-07	3.21e-06	32
GO:007147819	Thyroid	PTC	cellular response to radiation	93/5968	186/18723	1.90e-07	3.51e-06	93
GO:001701515	Thyroid	PTC	regulation of transforming growth factor beta receptor signaling pathway	69/5968	128/18723	1.92e-07	3.51e-06	69
GO:0051235112	Thyroid	PTC	maintenance of location	148/5968	327/18723	2.30e-07	4.07e-06	148
GO:190332210	Thyroid	PTC	positive regulation of protein modification by small protein conjugation or removal	73/5968	138/18723	2.34e-07	4.11e-06	73
GO:190384415	Thyroid	PTC	regulation of cellular response to transforming growth factor beta stimulus	70/5968	131/18723	2.47e-07	4.31e-06	70
GO:0009267112	Thyroid	PTC	cellular response to starvation	80/5968	156/18723	3.52e-07	5.90e-06	80
GO:0009314111	Thyroid	PTC	response to radiation	195/5968	456/18723	5.10e-07	8.27e-06	195
GO:0031667113	Thyroid	PTC	response to nutrient levels	201/5968	474/18723	7.00e-07	1.10e-05	201
GO:007259918	Thyroid	PTC	establishment of protein localization to endoplasmic reticulum	31/5968	46/18723	8.06e-07	1.24e-05	31
GO:1903573113	Thyroid	PTC	negative regulation of response to endoplasmic reticulum stress	30/5968	44/18723	8.27e-07	1.27e-05	30
GO:000717819	Thyroid	PTC	transmembrane receptor protein serine/threonine kinase signaling pathway	156/5968	355/18723	1.02e-06	1.51e-05	156
GO:0043620113	Thyroid	PTC	regulation of DNA-templated transcription in response to stress	34/5968	53/18723	1.36e-06	1.95e-05	34
GO:00313989	Thyroid	PTC	positive regulation of protein ubiquitination	63/5968	119/18723	1.47e-06	2.08e-05	63
GO:0043618113	Thyroid	PTC	regulation of transcription from RNA polymerase II promoter in response to stress	31/5968	47/18723	1.64e-06	2.30e-05	31
GO:0051651113	Thyroid	PTC	maintenance of location in cell	100/5968	214/18723	3.65e-06	4.67e-05	100
GO:004504716	Thyroid	PTC	protein targeting to ER	28/5968	42/18723	3.83e-06	4.80e-05	28

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0501218	Breast	Precancer	Parkinson disease	99/684	266/8465	3.58e-42	5.65e-40	4.33e-40	99
hsa0502016	Breast	Precancer	Prion disease	95/684	273/8465	1.39e-37	1.46e-35	1.12e-35	95
hsa0501416	Breast	Precancer	Amyotrophic lateral sclerosis	98/684	364/8465	2.13e-28	8.41e-27	6.44e-27	98
hsa0502216	Breast	Precancer	Pathways of neurodegeneration - multiple diseases	112/684	476/8465	6.96e-27	2.44e-25	1.87e-25	112
hsa0414118	Breast	Precancer	Protein processing in endoplasmic reticulum	33/684	174/8465	2.78e-06	3.83e-05	2.94e-05	33
hsa0541718	Breast	Precancer	Lipid and atherosclerosis	37/684	215/8465	7.64e-06	9.29e-05	7.12e-05	37
hsa0461218	Breast	Precancer	Antigen processing and presentation	19/684	78/8465	9.61e-06	1.12e-04	8.62e-05	19
hsa030609	Breast	Precancer	Protein export	6/684	23/8465	8.34e-03	4.54e-02	3.48e-02	6
hsa0501219	Breast	Precancer	Parkinson disease	99/684	266/8465	3.58e-42	5.65e-40	4.33e-40	99
hsa0502017	Breast	Precancer	Prion disease	95/684	273/8465	1.39e-37	1.46e-35	1.12e-35	95
hsa0501417	Breast	Precancer	Amyotrophic lateral sclerosis	98/684	364/8465	2.13e-28	8.41e-27	6.44e-27	98
hsa0502217	Breast	Precancer	Pathways of neurodegeneration - multiple diseases	112/684	476/8465	6.96e-27	2.44e-25	1.87e-25	112
hsa0414119	Breast	Precancer	Protein processing in endoplasmic reticulum	33/684	174/8465	2.78e-06	3.83e-05	2.94e-05	33
hsa0541719	Breast	Precancer	Lipid and atherosclerosis	37/684	215/8465	7.64e-06	9.29e-05	7.12e-05	37
hsa0461219	Breast	Precancer	Antigen processing and presentation	19/684	78/8465	9.61e-06	1.12e-04	8.62e-05	19
hsa0306012	Breast	Precancer	Protein export	6/684	23/8465	8.34e-03	4.54e-02	3.48e-02	6
hsa0501224	Breast	IDC	Parkinson disease	107/867	266/8465	2.57e-39	8.36e-37	6.26e-37	107
hsa0502023	Breast	IDC	Prion disease	102/867	273/8465	3.70e-34	4.01e-32	3.00e-32	102
hsa0501423	Breast	IDC	Amyotrophic lateral sclerosis	102/867	364/8465	1.29e-22	5.22e-21	3.91e-21	102
hsa0502223	Breast	IDC	Pathways of neurodegeneration - multiple diseases	116/867	476/8465	3.63e-20	1.18e-18	8.82e-19	116

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

HSPA5

SNV

Missense_Mutation

c.887N>C

p.Lys296Thr

p.K296T

P11021

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.997)

TCGA-A8-A08Z-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

HSPA5

SNV

Missense_Mutation

c.211N>A

p.Glu71Lys

p.E71K

P11021

protein_coding

deleterious_low_confidence(0.03)

benign(0.02)

TCGA-AC-A2B8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

chemo

HSPA5

SNV

Missense_Mutation

novel

c.414N>T

p.Lys138Asn

p.K138N

P11021

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.902)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HSPA5

SNV

Missense_Mutation

rs368840257

c.1595G>A

p.Arg532His

p.R532H

P11021

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.956)

TCGA-AN-A0AK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HSPA5

SNV

Missense_Mutation

c.1540N>C

p.Glu514Gln

p.E514Q

P11021

protein_coding

tolerated_low_confidence(0.24)

probably_damaging(0.982)

TCGA-D8-A1JA-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

HSPA5

SNV

Missense_Mutation

rs191087735

c.395N>C

p.Ile132Thr

p.I132T

P11021

protein_coding

tolerated_low_confidence(0.13)

benign(0.012)

TCGA-E2-A56Z-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

HSPA5

SNV

Missense_Mutation

novel

c.433N>G

p.Ile145Val

p.I145V

P11021

protein_coding

tolerated_low_confidence(0.38)

benign(0.011)

TCGA-S3-AA12-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

anastrozole

HSPA5

SNV

Missense_Mutation

rs762582529

c.971N>A

p.Arg324Gln

p.R324Q

P11021

protein_coding

deleterious_low_confidence(0.03)

benign(0.368)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

HSPA5

SNV

Missense_Mutation

c.1712N>A

p.Ser571Tyr

p.S571Y

P11021

protein_coding

tolerated_low_confidence(0.05)

benign(0.114)

TCGA-CA-6718-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

HSPA5

SNV

Missense_Mutation

novel

c.949N>T

p.Asp317Tyr

p.D317Y

P11021

protein_coding

deleterious_low_confidence(0)

probably_damaging(1)

TCGA-AG-3892-01

Colorectum

rectum adenocarcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
3309	HSPA5	TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME		STROBOPININ	STROBOPININ
3309	HSPA5	TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME		TCMDC-123749	CHEMBL524376
3309	HSPA5	TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME		NORGESTREL	NORGESTREL
3309	HSPA5	TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME		MIANSERIN	MIANSERIN
3309	HSPA5	TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME		AG-490	CHEMBL56543
3309	HSPA5	TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME		CHLORQUINALDOL	CHLORQUINALDOL
3309	HSPA5	TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME		SAM-6
3309	HSPA5	TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME		5-NITRO-2-PHENYLPROPYLAMINOBENZOIC ACID [NPPB]	5-NITRO-2-PHENYLPROPYLAMINOBENZOIC ACID [NPPB]
3309	HSPA5	TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME		THAPSIGARGIN	THAPSIGARGIN
3309	HSPA5	TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME		NKP-1339	IT-139

Page: 1 2